Celldex Therapeutics, Inc. (CLDX) shareholders
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (10.70%) | 8,411,905 | 10.70% | 13G (passive) amendment | Sep 30, 2026 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (12.20%), Wellington Investment Advisors Holdings LLP (12.20%) and 1 more | 8,079,608 | 12.20% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (7.90%), Wellington Investment Advisors Holdings LLP (7.90%) and 1 more | 5,232,326 | 7.90% | 13G (passive) amendment | Jun 30, 2025 |
| FMR LLC Joint filing with Abigail P. Johnson (7.30%) | 4,857,668 | 7.30% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 4,819,293 | 7.30% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Associates, Inc. | 4,686,187 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (6.70%), Steven A. Cohen (6.70%) | 4,464,400 | 6.70% | 13G (passive) | Jul 2, 2025 |
| Vanguard Capital Management | 3,446,795 | 5.17% | 13G (passive) | Mar 31, 2026 |
| Kynam Capital Management, LP Joint filing with Kynam Capital Management GP, LLC (6.78%), Yue Tang (6.78%) | 0 | 6.78% | 13G (passive) amendment | Jun 30, 2026 |
| Kynam Capital Management GP, LLC Joint filing with Kynam Capital Management, LP (8.77%), Yue Tang (8.77%) | 0 | 8.77% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wellington Management Group Llp | 9,543,671 | 12.15% | $355.12M | +983,195 | 0.06% |
| BlackRock, Inc. | 7,002,530 | 8.92% | $260.56M | +1,632,645 | 0.00% |
| Kynam Capital Management, LP | 5,322,908 | 6.78% | $198.07M | −517,659 | 10.95% |
| Price T Rowe Associates Inc /Md/ | 4,685,223 | 5.97% | $174.34M | +2,598,891 | 0.02% |
| State Street Corp | 3,900,427 | 4.97% | $145.13M | +1,096,259 | 0.00% |
| FMR LLC | 3,722,888 | 4.74% | $138.53M | −26,160 | 0.01% |
| Vanguard Capital Management LLC | 3,464,831 | 4.41% | $128.93M | +503,936 | 0.00% |
| Deep Track Capital, LP | 2,939,151 | 3.74% | $109.37M | +1,655,172 | 1.59% |
| Logos Global Management LP | 2,100,000 | 2.67% | $78.14M | +1,650,000 | 3.36% |
| Geode Capital Management, LLC | 2,022,226 | 2.58% | $75.26M | +334,152 | 0.00% |
| Eversept Partners, LP | 1,785,941 | 2.27% | $66.45M | −2,075 | 3.45% |
| Goldman Sachs Group Inc | 1,615,343 | 2.06% | $60.11M | +626,927 | 0.01% |
| Assenagon Asset Management S.A. | 1,577,392 | 2.01% | $58.69M | +1,430,867 | 0.04% |
| Commodore Capital LP | 1,350,000 | 1.72% | $50.23M | −1,346,616 | 2.99% |
| Bellevue Group AG | 1,200,000 | 1.53% | $44.65M | – | 0.94% |
| Baker Bros. Advisors LP | 1,182,611 | 1.51% | $44.00M | +517,241 | 0.22% |
| Millennium Management LLC | 1,170,787 | 1.49% | $43.56M | −82,745 | 0.02% |
| Dimensional Fund Advisors LP | 1,073,985 | 1.37% | $39.96M | +14,451 | 0.01% |
| American Century Companies Inc | 1,042,395 | 1.33% | $38.79M | +186,085 | 0.02% |
| Eventide Asset Management, LLC | 1,037,000 | 1.32% | $38.59M | – | 0.52% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 253 | 86M | 100.0% | 49 / 106 | 57 / 21 | 22M | 9M |
| Q1 2026 | 228 | 73M | 92.7% | 59 / 68 | 58 / 14 | 13M | 9M |
| Q4 2025 | 186 | 73M | 93.3% | 25 / 59 | 59 / 21 | 9M | 6M |
| Q3 2025 | 184 | 71M | 90.3% | 31 / 60 | 56 / 26 | 7M | 9M |
| Q2 2025 | 180 | 72M | 92.2% | 38 / 74 | 43 / 28 | 8M | 10M |
| Q1 2025 | 171 | 74M | 93.8% | 29 / 64 | 52 / 31 | 10M | 10M |
| Q4 2024 | 174 | 74M | 93.8% | 34 / 65 | 49 / 36 | 13M | 11M |
| Q3 2024 | 176 | 72M | 91.5% | 23 / 66 | 56 / 29 | 15M | 8M |
| Q2 2024 | 183 | 70M | 88.9% | 25 / 81 | 49 / 36 | 7M | 8M |
| Q1 2024 | 197 | 70M | 89.3% | 47 / 80 | 44 / 13 | 17M | 9M |
| Q4 2023 | 164 | 62M | 78.8% | 33 / 61 | 44 / 11 | 13M | 2M |
| Q3 2023 | 143 | 51M | 64.4% | 15 / 61 | 42 / 21 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
246 funds held CLDX in Q2 2026, 35% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CLDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 3,783,994 | 4.82% | $144.02M | 0.38% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,487,758 | 3.17% | $92.57M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,032,138 | 2.59% | $75.62M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,026,087 | 2.58% | $75.39M | 0.70% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,447,608 | 1.84% | $55.10M | 0.25% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,254,603 | 1.60% | $46.68M | 0.32% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,037,000 | 1.32% | $38.59M | 2.16% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 970,814 | 1.24% | $36.12M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 897,530 | 1.14% | $33.40M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 854,702 | 1.09% | $32.53M | 0.10% | Jul 31, 2026 |
| Small Cap Growth Fund | 793,241 | 1.01% | $30.19M | 0.54% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 579,456 | 0.74% | $21.56M | 0.14% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 530,328 | 0.68% | $20.18M | 0.41% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 512,352 | 0.65% | $19.50M | 0.89% | Jul 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 512,299 | 0.65% | $16.10M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Anthony S. Marucci | PRESIDENT & CEO, Director | 40,284 | 0.05% | Jun 29, 2026 |
| Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | 12,610 | 0.02% | Jun 29, 2026 |
| Samuel Bates Martin | SVP AND CFO | 32,942 | 0.04% | Jun 29, 2026 |
| Margo Heath-Chiozzi | SVP OF REGULATORY AFFAIRS | 13,383 | 0.02% | Jun 29, 2026 |
| Diane C. Young | SVP, CHIEF MEDICAL OFFICER | 17,115 | 0.02% | Jun 29, 2026 |
| Freddy A. Jimenez | SVP & GENERAL COUNSEL | 30,796 | 0.04% | Jun 29, 2026 |
| Ronald Pepin | SR. VP & CBO | 20,097 | 0.03% | Jun 29, 2026 |
| Tibor Keler | EXECUTIVE VP & CSO | 24,217 | 0.03% | Jun 29, 2026 |
| Elizabeth Crowley | SR. VP & CPDO | 39,074 | 0.05% | Jun 29, 2026 |
| Teri L. Lawver | SVP & Chief Commercial Officer | – | – | Jun 29, 2026 |
| Cheryl Cohen | Director | – | – | Jun 29, 2026 |
| Rita Jain | Director | – | – | Jun 29, 2026 |
| Harry Penner Jr | Director | 41,916 | 0.05% | Jun 29, 2026 |
| Herbert J. Conrad | Director | 38,500 | 0.05% | Jun 29, 2026 |
| Keith L. Brownlie | Director | 10,000 | 0.01% | Jun 29, 2026 |
| James J. Marino | Director | 2,204 | 0.00% | Jun 29, 2026 |
| Garry Arthur Neil | Director | – | – | Jun 29, 2026 |
| Denice Torres | Director | – | – | Jun 29, 2026 |
| Richard M. Wright | – | 70,131 | 0.09% | Nov 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Samuel Bates Martin SVP AND CFO | Jan 2, 2026 | Option exercise | +4,817 | $10.38 | $50.00K | 32,942 |
| Ronald Pepin SR. VP & CBO | Dec 15, 2025 | Option exercise | +11,000 | $2.78 | $30.58K | 20,097 |
| Ronald Pepin SR. VP & CBO | Dec 15, 2025 | Option exercise | +8,333 | $9.02 | $75.16K | 9,097 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Dec 4, 2025 | Sale | −4,166 | $29.10 | $121.23K | 30,796 |
| Richard M. Wright – | Nov 13, 2025 | Option exercise | +15,750 | $22.48 | $354.06K | 70,131 |
| Richard M. Wright – | Nov 13, 2025 | Option exercise | +26,672 | $10.38 | $276.86K | 54,381 |
| Richard M. Wright – | Nov 13, 2025 | Option exercise | +6,876 | $9.02 | $62.02K | 27,709 |
| Richard M. Wright – | Nov 13, 2025 | Sale | −49,298 | $24.00 | $1.18M | 20,833 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Aug 13, 2025 | Sale | −430 | $25.42 | $10.93K | 34,962 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Aug 13, 2025 | Sale | −341 | $23.95 | $8.17K | 35,392 |
| James J. Marino Director | Nov 18, 2024 | Gift | −10,500 | – | – | 2,204 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Nov 11, 2024 | Buy | +11,500 | $26.82 | $308.43K | 40,284 |
| Samuel Bates Martin SVP AND CFO | Jun 14, 2024 | Option exercise | +3,201 | $9.02 | $28.87K | 28,329 |
| Samuel Bates Martin SVP AND CFO | Jun 14, 2024 | Option exercise | +16,968 | $10.38 | $176.13K | 45,297 |
| Samuel Bates Martin SVP AND CFO | Jun 14, 2024 | Sale | −17,172 | $35.42 | $608.23K | 28,125 |
| Elizabeth Crowley SR. VP & CPDO | Jun 14, 2024 | Option exercise | +30,000 | $10.38 | $311.40K | 39,074 |
| Elizabeth Crowley SR. VP & CPDO | Jun 14, 2024 | Sale | −30,000 | $34.87 | $1.05M | 9,074 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Jun 11, 2024 | Option exercise | +15,000 | $2.71 | $40.65K | 17,115 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Jun 7, 2024 | Sale | −45,000 | $35.26 | $1.59M | 2,115 |
| Elizabeth Crowley SR. VP & CPDO | Jun 7, 2024 | Option exercise | +7,500 | $10.38 | $77.85K | 16,574 |
| Elizabeth Crowley SR. VP & CPDO | Jun 7, 2024 | Sale | −15,000 | $35.06 | $525.90K | 9,074 |
| Elizabeth Crowley SR. VP & CPDO | Jun 7, 2024 | Option exercise | +7,500 | $9.02 | $67.65K | 24,074 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Jun 5, 2024 | Option exercise | +9,540 | $10.38 | $99.03K | 35,464 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | Jun 3, 2024 | Sale | −58,369 | $33.65 | $1.96M | 13,383 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | Jun 3, 2024 | Option exercise | +58,369 | $10.38 | $605.87K | 71,752 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | Jun 3, 2024 | Option exercise | +6,289 | $9.02 | $56.73K | 13,383 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Option exercise | +28,469 | $28.00 | $797.13K | 49,302 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Sale | −19,264 | $33.99 | $654.78K | 20,833 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Option exercise | +20,625 | $2.78 | $57.34K | 20,833 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Sale | −27,580 | $33.53 | $924.76K | 40,097 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Option exercise | +18,375 | $22.48 | $413.07K | 67,677 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Jun 3, 2024 | Sale | −8,006 | $33.60 | $269.00K | 25,924 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Jun 3, 2024 | Option exercise | +8,006 | $10.38 | $83.10K | 33,930 |
| Elizabeth Crowley SR. VP & CPDO | May 30, 2024 | Sale | −38,597 | $33.64 | $1.30M | 9,074 |
| Elizabeth Crowley SR. VP & CPDO | May 30, 2024 | Option exercise | +34,445 | $2.78 | $95.76K | 39,171 |
| Elizabeth Crowley SR. VP & CPDO | May 30, 2024 | Option exercise | +8,500 | $9.02 | $76.67K | 47,671 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | May 30, 2024 | Option exercise | +10,750 | $2.78 | $29.88K | 12,610 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | May 30, 2024 | Option exercise | +10,103 | $9.02 | $91.13K | 22,713 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | May 30, 2024 | Sale | −20,853 | $33.73 | $703.37K | 1,860 |
| Samuel Bates Martin SVP AND CFO | May 30, 2024 | Option exercise | +25,000 | $10.38 | $259.50K | 60,128 |
| Samuel Bates Martin SVP AND CFO | May 30, 2024 | Sale | −35,000 | $34.05 | $1.19M | 25,128 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Sale | −38,719 | $34.07 | $1.32M | 7,094 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Option exercise | +29,068 | $2.78 | $80.81K | 41,162 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Option exercise | +2,043 | $9.02 | $18.43K | 43,205 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Option exercise | +2,608 | $10.38 | $27.07K | 45,813 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Feb 13, 2024 | Option exercise | +20,000 | $2.78 | $55.60K | 25,924 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Feb 13, 2024 | Option exercise | +4,166 | $9.02 | $37.58K | 5,924 |
| Samuel Bates Martin SVP AND CFO | Jan 2, 2024 | Option exercise | +10,750 | $2.78 | $29.88K | 35,128 |
| Tibor Keler EXECUTIVE VP & CSO | Dec 7, 2022 | Option exercise | +16,860 | $2.78 | $46.87K | 24,217 |
| Tibor Keler EXECUTIVE VP & CSO | Dec 7, 2022 | Sale | −16,860 | $36.93 | $622.64K | 7,357 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 18, 2022 | Sale | −1,355 | $36.38 | $49.29K | 1,284 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 18, 2022 | Option exercise | +1,355 | $9.02 | $12.22K | 2,639 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 17, 2022 | Option exercise | +31,312 | $2.78 | $87.05K | 32,596 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 17, 2022 | Sale | −31,312 | $36.73 | $1.15M | 1,284 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Aug 17, 2022 | Option exercise | +19,000 | $10.38 | $197.22K | 21,115 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Aug 17, 2022 | Sale | −19,000 | $37.30 | $708.70K | 2,115 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Aug 17, 2022 | Option exercise | +45,000 | $2.71 | $121.95K | 47,115 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Aug 15, 2022 | Option exercise | +45,000 | $9.02 | $405.90K | 147,692 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Aug 15, 2022 | Option exercise | +75,000 | $2.78 | $208.50K | 102,692 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Aug 15, 2022 | Sale | −120,000 | $37.66 | $4.52M | 27,692 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Celldex Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 54,085 shares on Sep 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Freddy A. Jimenez Officer | Dec 4, 2025 | 4,166 | $121.21K | Dec 4, 2025 | Exercised Shares |
| Richard M. Wright Officer | Nov 13, 2025 | 49,298 | $1.18M | Nov 13, 2025 | Stock Option Exercise |
| Samuel Bates Martin Officer | Jun 14, 2024 | 17,172 | $583.85K | Jun 14, 2024 | STOCK OPTION EXERCISE |
| Elizabeth Crowley Officer | Jun 14, 2024 | 30,000 | $1.02M | Jun 14, 2024 | STOCK OPTION EXERCISE |
| Diane C. Young Officer | Jun 7, 2024 | 45,000 | $1.59M | Jun 7, 2024 | EXERCISED SHARES |
| Elizabeth Crowley Officer | Jun 7, 2024 | 15,000 | $510.00K | Jun 7, 2024 | STOCK OPTION EXERCISE |
| Richard M. Wright Officer | Jun 3, 2024 | 46,844 | $1.50M | Jun 3, 2024 | STOCK OPTION EXERCISE |
| Freddy A. Jimenez Officer | Jun 3, 2024 | 8,006 | $269.00K | Jun 3, 2024 | STOCK OPTION EXERCISE |
| Margo Heath-Chiozzi Director | May 30, 2024 | 97,088 | $3.53M | May 30, 2024 | STOCK OPTION EXERCISE |
| Sarah Cavanaugh Officer | May 30, 2024 | 20,853 | $703.33K | May 30, 2024 | STOCK OPTION EXERCISE |
| Elizabeth Crowley Officer | May 30, 2024 | 38,597 | $144.00K | May 30, 2024 | STOCK OPTION EXERCISE |
| Samuel Bates Martin Officer | May 30, 2024 | 35,000 | $1.19M | May 30, 2024 | ESPP |
See a number that looks wrong?